The medications you prescribe may leave lasting fingerprints on the trillions of microbes in your patients’ guts, reshaping those ecosystems in ways scientists are finally starting to understand.

When Stanford University researchers mapped the different ways drugs feed or starve certain species, they found that many drugs — including benzodiazepines as well as the topical antifungal oxiconazole — can seriously disrupt the gut microbiome. Their in vitro work spanned roughly 700 drugs, and 140 of them had notable microbiome effects.

Takeaway: A drug’s class has little to do with its impact on the gut.

“In my mind, there isn’t a story about a single drug,” said senior study author K.C. Huang, PhD, professor of microbiology and immunology at Stanford University in Stanford, California. “They all have different effects. But by understanding how they affect each species, we can create a model for how they affect the whole community.”

The researchers used the data to develop a framework for predicting how a patient’s microbiome will shift in response to treatment — potentially allowing physicians to anticipate a drug’s side effects and effectiveness before the prescription is even written.

How Drugs Reshape the Microbiome

This latest study and others mark a crucial shift in microbiome research. Instead of focusing on one-size-fits-all therapy such as probiotics, researchers are gaining tools for a more personalized approach: predicting who will thrive on a treatment vs who will see no benefit.

As Geoffrey Preidis, MD, PhD, microbiome researcher at Baylor College of Medicine in Houston, put it, the field is finally moving away from simply cataloging microbes and comparing them toward the more clinically useful goal of “predicting which individual is going to respond” as intended.

A September study in mSystems reported that many medications — including antibiotics, psycholeptics, antidepressants, proton pump inhibitors, and beta-blockers — are associated with shifts in the gut microbiome when people start or stop taking them, a pattern that suggests the drugs are driving the changes.

Microbiome changes linked to benzodiazepines lasted for several years and were roughly as strong as those seen with broad‑spectrum antibiotics.

The analysis included national biobank stool sample data from 2509 people, with additional data from a 328-person subcohort who provided a second stool sample 3 years later.

Huang’s team also delved into persistence.

Most of the time, the drugs’ effects on the microbiome could be reversed with the lab equivalent of a fecal transplant, they found. But not always: The antibiotic levofloxacin had effects that couldn’t be restored.

That’s because another organism — a pathobiont — had already taken over the microbiome and switched it to a stable state, Huang said. “So by adding this antibiotic, we were opening up the potential for a pathogen to take control of the system and prevent the fecal transplant from working.”

When Diet Gets in the Way of Recovery

Another recent study, in Nature, showed that restoration efforts such as fecal transplants can be undermined by a high-fat, low-fiber diet.

Mice fed such a diet after antibiotic treatment struggled to recover from dysbiosis, while those given a high-fiber, low-fat diet recovered faster. Even fecal transplants failed to restore microbial balance when up against a poor diet.

Taken together, the three studies tell a compelling story, said Alexa Weingarden, MD, PhD, assistant professor of gastroenterology, hepatology, and nutrition at the University of Minnesota, Minneapolis. But to make the findings clinically useful, scientists need to decide what “recovery” actually looks like — whether the goal is a microbiome that fully rebounds after disruption or one that can function despite lasting changes. “Do we need a resilient gut microbiome?” she said. “Or is a somewhat resilient one enough?”

The Limits — and Promise — of Fecal Transplants

Huang’s team found that most gut microbial communities bounced back over time.

“With very few exceptions, [fecal transplant] can be incredibly effective,” Huang said.

Applying these treatments in the clinic isn’t straightforward, but the approach holds promise, Huang said. “I certainly have banks of my own stool that I’m keeping for anytime something does go wrong.”

Weingarden reported holding a patent for compositions and methods for transplantation of colon microbiota (US Patent 2014/0147417 A1, filed March 9, 2012, accepted May 29, 2014).